ReviewLung2022
Chronic Thromboembolic Pulmonary Hypertension.
Review in Lung, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of Fibrinogen Aα Thr312Ala (rs6050) Polymorphism with Venous Thrombosis and Chronic Thromboembolic Pulmonary Hypertension: A Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Predictors of long-term survival after pulmonary endarterectomy.JTCVS open · 2026Article
- Dual-energy CT based scoring to estimate perfusion changes after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.JHLT open · 2026Article
- Understanding the Impact of Hypoxia on Pulmonary Artery Endothelial Cells in Chronic Thromboembolic Pulmonary Hypertension Patients.International journal of molecular sciences · 2026Article
- The role of ventilation/perfusion scintigraphy in distinguishing acute from chronic pulmonary embolism.Emergency radiology · 2026Article
- Notch signaling enhances PASMC proliferation and vascular remodeling in CTEPH.Open life sciences · 2026Article
- Factors affecting patient outcomes in pulmonary artery thromboendarterectomy under deep hypothermic circulatory arrest and cardiopulmonary bypass support----a single center's experience.BMC cardiovascular disorders · 2025Article
- The Predictive Value of Quantitative Analysis of SPECT V/Q Imaging for Postoperative Persistent/Recurrent Pulmonary Hypertension in Patients With Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy.Pulmonary circulation · 2025Article
- Off-label use of treprostinil in adult patients in clinical cases.World journal of clinical cases · 2025Review
- Assessment of Right Ventricular Pressure in Chronic Thromboembolic Pulmonary Hypertension: Comparison of Diagnostic Modalities and Balloon Pulmonary Angioplasty Outcomes.Diagnostics (Basel, Switzerland) · 2025Article
- Utility of Clustering in Mortality Risk Stratification in Pulmonary Hypertension.Bioengineering (Basel, Switzerland) · 2025Article
- Efficacy and influencing factors of thrombolytic therapy in patients with pulmonary embolism complicated y pulmonary arterial hypertension.American journal of translational research · 2025Article
- Circular RNAs in Heart Diseases.Advances in experimental medicine and biology · 2025Review
- The use of imaging in the diagnosis and treatment of thromboembolic pulmonary hypertension.Cardiology journal · 2025Review
- Effects of balloon pulmonary angioplasty on cardiac and pulmonary functions and complications in patients with chronic thromboembolic pulmonary hypertension.Frontiers in medicine · 2025Article
- Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study.BMC pulmonary medicine · 2024Article
- Quantitative assessment of pulmonary blood flow redistribution in the classification of group 1 and group 4 pulmonary hypertension.Quantitative imaging in medicine and surgery · 2024Article
- Controlling Nutritional Status Score Predicts 1-Year Outcomes in Chronic Thromboembolic Pulmonary Hypertension.Circulation reports · 2024Article
- The Importance of Topographical Recognition of Pulmonary Arteries in Diagnostics and Treatment of CTEPH, Based on an Analysis of a Dissected Case Model-A Pilot Study.Diagnostics (Basel, Switzerland) · 2024Article
- Investigation into the role of H2-Ab1 in vascular remodeling in pulmonary arterial hypertension via Bioinformatics.BMC pulmonary medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary pulmonary hypertension (PH) by right heart catheterization and imaging consistent with chronic thromboembolism, is a long-term complication of pulmonary embolism (PE). Pathobiological mechanisms involve pulmonary artery occlusion from organized thromboembolic material despite at least three months of uninterrupted therapeutic anticoagulation following acute PE and secondary microvasculopathy. Delay in diagnosis and management of CTEPH is associated with poor outcomes. High clinical suspicion, comprehensive assessment of residual dyspnea or exercise intolerance in the aftermath of PE and accurate interpretation of computed tomography pulmonary angiography (CTPA) are pivotal steps in the diagnosis. Ventilation-perfusion (V/Q) scan is the preferred initial radiologic screening tool as normal V/Q essentially rules out CTEPH. Any mismatched perfusion defect on the V/Q scan in the setting of PH or any finding compatible with chronic thromboembolism on CTPA should prompt referral to an expert CTEPH center. Once the diagnosis is verified, all eligible patients should be offered pulmonary thromboendarterectomy (PTE). Pulmonary vasodilators or balloon pulmonary angioplasty are safe and effective in inoperable or post-PTE persistent/recurrent CTEPH. During the course of their disease, a patient may receive a combination of treatments, at times consisting of all three strategies. Lifelong therapeutic anticoagulation is recommended for CTEPH.
Indexed as
Identifiers
35643802What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.